XML 71 R54.htm IDEA: XBRL DOCUMENT v3.25.4

License Agreements & Ducentis Acquisition - AstraZeneca (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	May 31, 2025	Oct. 31, 2024	Sep. 30, 2022	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amortization of intangible assets				$ 4,667	$ 1,959	$ 750
Years from first commercial sale				10 years
AstraZeneca
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Product milestone payment for first product approval			$ 7,500
Sales milestone payment	$ 10,000	$ 5,000
Annual net sales	$ 250,000	$ 100,000
Intangible asset, useful life (in years)			10 years
Amortization of intangible assets				$ 4,700	2,000	800
Maximum milestone payments for licensed products				5,000
Royalty expense				$ 11,200	$ 5,000	$ 900

X

- Definition

Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold

+ References

No definition available.

+ Details

Name:	arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersAnnualWorldwideNetSalesThreshold
Namespace Prefix:	arqt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval

+ References

No definition available.

+ Details

Name:	arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePaymentForFirstProductApproval
Namespace Prefix:	arqt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments

+ References

No definition available.

+ Details

Name:	arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersProductMilestonePayments
Namespace Prefix:	arqt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments

+ References

No definition available.

+ Details

Name:	arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersSalesMilestonePayments
Namespace Prefix:	arqt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Research and Development Arrangement, Contract to Perform for Others, Years From First Commercial Sale

+ References

No definition available.

+ Details

Name:	arqt_ResearchAndDevelopmentArrangementContractToPerformForOthersYearsFromFirstCommercialSale
Namespace Prefix:	arqt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=arqt_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: